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Pathogenic properties of mutant SOD1 in ALS likely involve binding to mitochondrial and ER membranes.
In this issue of Neuron, Israelson et al. (2015) show that motor neurons, selectively vulnerable in ALS, lack
a chaperone that precludes mSOD1 binding intracellular membranes in other cells. This chaperone is
identified as the pleiotropic cytokine macrophage migration inhibitory factor.That Zelig could be responsible
for the behavior of each of the
personalities he assumed means
dozens of lawsuits. He is sued
for bigamy, adultery, automobile
accidents, plagiarism, household
damages, negligence, property
damages, and performing unnec-
essary dental extractions.
—Zelig (1983), written by
Woody Allen
Mutant forms of cytoplasmic Cu/Zn
superoxide dismutase (SOD1), a ubiqui-
tously expressed protein, cause amyotro-
phic lateral sclerosis (ALS) with selective
degeneration in the CNS motor system.
ALS incident cases in the United States
approximately equal those of multiple
sclerosis (MS), but ALS prevalence is
far lower due to its virulent lethality.
More than 100 ALS-associated SOD1
mutations (collectively termed mSOD1),
including many which leave catalytic
function unaffected, have been des-
cribed. Cellular phenotypes associated
with mutant SOD1, which accounts for
about 20% of familial ALS cases, have
also been described in sporadic ALS,
lending urgency to the deciphering of its
pathogenic mechanisms.
Providing a potential clue to its relation
to ALS pathogenesis, mutant SOD1 binds
the cytosolic face of mitochondrial
membranes and to ER selectively in
neuronal cells and CNS tissue lysates,
corresponding to the CNS-specific
degeneration seen in patients. Israelson
and coworkers (Israelson et al., 2015)2 Neuron 86, April 8, 2015 ª2015 Elsevier Incaddressed this neuronal specificity by
asking the following question: is there an
activity in neurons which drives SOD1
binding tomitochondria, or is a binding in-
hibitor present in non-neuronal cells?
Their results indicated that non-neuronal
cytosol contains a protein which inhibits
SOD1 binding to mitochondria, and they
identified this activity as macrophage
migration inhibitory factor (MIF). This
result will provoke curiosity in those
who’ve never heard of MIF and a sigh of
bemused, perhaps weary, recognition
for those who’ve followed MIF’s 40-year
odyssey through biomedicine.
Characterized in 1966 as a factor
secreted by lymphocytes (Bloom and
Bennett, 1966; David, 1966), MIF was
among the earliest-studied cytokines
and has accumulated a bewildering vari-
ety of functions which account for its
ability to appear in ever-changing guises
in a seemingly endless series of biological
contexts (Bucala, 2012). Interwoven cell-
autonomous, autocrine, paracrine, and
organism-wide activities consistently
emerge in studies of MIF biology. In the
immune system, MIF exhibits inflamma-
tory cytokine activity and also enhances
immunological processes through direct
inhibitory effects on glucocorticoid action
(Bernhagen et al., 1993). Surprisingly
(but not for MIF), the anterior pituitary is
a major source of MIF in the setting of
endotoxemia (Bucala, 1996).
MIF homologs are widely expressed
throughout biology with representative
family members found in C. elegans
and Danio rerio (Vermeire et al., 2008),
where the MIF homolog is required for.CNS organogenesis. Microbial species
including Rickettsia also express MIF-
like proteins (Calandra and Roger, 2003).
In solution, MIF is a homotrimer, and
this tertiary structure is stringently con-
served for MIF homologs, while amino
acid identities are not. Ketoenol tautomer-
ase activity toward organic substrates
such as phenylpyruvate is also conserved
both in animal and bacterial MIF family
proteins. Thiol reductase activity is
considered important for MIF’s cardio-
protective action in acute myocardial
infarction by reducing oxidative stress,
thereby suppressing apoptotic signaling
(Miller et al., 2008).
In its non-cell-autonomous functions,
MIF mediates receptor-dependent cyto-
kine-characteristic paracrine and auto-
crine signaling, binding homotrimeric
CD74. Binding is, however, insufficient
for cellular responses, as the ligated
receptor must complex with CD44 to
activate Src upstream of Raf-1, leading
to Erk1 phosphorylation and transcrip-
tion of MAP kinase pathway genes (Shi
et al., 2006). In parallel, MIF inhibits
c-Jun N-terminal activation domain-bind-
ing protein-1 (JAB-1), suppressing Jnk
signaling and prolonging activation of
phospho-Erk1 (Kleemann et al., 2000).
Much of MIF’s receptor-mediated action
relies on cAMP-dependent protein kinase
(PKA), making it somewhat paradoxical
that a counter-regulatory enzyme AMP-
activated kinase (AMPK) is considered a
key effector of MIF’s cardioprotective
function (Miller et al., 2008). One cell’s
cytoprotection is of course another cell’s
release from physiological growth control.
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diac myocyte survival in the ischemic
heart have been found to promote leuke-
mogenesis in B cell lymphoma cells (Sha-
char and Haran, 2011).
The film Zelig recounts the fictional
saga of a man who takes on the appear-
ance and behavior of those around him,
leading to his nickname ‘‘The Human
Chameleon.’’ Given its array of intracel-
lular, intercellular, and systemic effects
in host defense, inflammatory disease,
ischemia, cancer, and (now) neurodegen-
eration, one might nominate MIF to be
the ‘‘Zelig of cytokines.’’
In the present study, Israelson et al.
(2015) proceeded to demonstrate that
MIF suppresses binding to mitochondria
and ER membranes in neuron-like NSC-
34 cells, and this assay was used to
demonstrate that MIF thiol reductase
activity was dispensable for inhibiting
mSOD1 binding to mitochondria, through
examination of a MIF point mutant. As
misfolded mSOD1 can be monitored
in vitro using a conformation-dependent
antibody DSE2, further studies could be
done in cell-free systems to demonstrate
that MIF reduces accumulation of DSE2
immunoreactivity. In this assay, the activ-
ity of purified MIF was equivalent to that
of liver cytosol, the input material used
to show that non-neuronal cells suppress
the binding of mSOD1 to mitochondrial
and ER membranes. Both catalytically
active and inactive forms of mSOD1
were used in these studies. The possibility
that MIF served as a chaperone for client
mSOD1 was addressed by coimmuno-
precipitation experiments showing that
MIF and SOD1 were physically asso-
ciated in cells, with an apparent Kd of
approximately 350 nM. Overexpression
of MIF (by lentiviral transduction) pro-
tected against the accelerated cell
death for iPSC-derived motor neurons
expressing mSOD1.
Why are motor neurons nearly devoid
of MIF protein by tissue immunostaining,which readily detects MIF in glia and in
other neurons? The mRNA is plentiful in
CNS neurons, macroglia, microglia, and
endothelial cells (http://web.stanford.
edu/group/barres_lab/cgi-bin/igv_cgi_2.
py?lname=Mif). Perhaps motor neurons
fail to transcribe, accumulate, or translate
MIF message. All three possibilities were
addressed directly in experiments using
choline acetyltransferase (ChAT)-bac-
TRAP mice to enable affinity isolation
and analysis of actively translatedmRNAs
in motor neurons. Quite unexpectedly,
it was shown that ChAT-positive motor
neurons abundantly produced MIF mes-
sage and protein in vivo. Near absence
of cytosolic MIF protein in motor neurons
must then reflect either or both of two
processes, MIF secretion or MIF degra-
dation, and these possibilities remain to
be discriminated. Also, it is unexplained
how lentiviral transduction, but not
endogenous MIF gene, maintains cyto-
protective levels of MIF protein.
In the present studies, SOD1 is a client
for MIF’s chaperone activity. Previous
research demonstrated that MIF also
provides chaperone function for insulin:
when secreted from Mif/ cells, insulin
shows reduced competence to drive
glucose uptake by hepatocytes (Vujicic
et al., 2014). Placing the potential roles
of MIF for ALS pathogenesis in context
of biology from other systems, it’s not
certain which functions beyond cell-
autonomous SOD1 chaperone activity
may also be implicated. While MIF is
exuberantly expressed in the CNS, the
localization of MIF-responsive receptors
remains uncertain: CD74 is strongly and
exclusively present on microglia, while
CD44 is mainly restricted to astrocytes.
MIF has been reported to induce matrix
metalloproteinase (MMP)-9, another ALS
suspect component in motor neurons
(Kaplan et al., 2014). In cancer cells, inhib-
iting heat-shock protein (HSP)-90 leads
to rapid degradation of MIF protein
(Schulz and Moll, 2014), so that it mayNeube worthwhile to examine whether a com-
parable pathway is involved in possible
destabilization of MIF protein in motor
neurons. Although it’s hard to predict
where this story will go from here, it can
be confidently anticipated that we’ll hear
much more from this protean molecule.REFERENCES
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